Liver-enriched HNF-3α and ubiquitous factors interact with the human transferrin gene enhancer  by Augé-Gouillou, Corinne et al.
Volume 323, number 1.2. 4-10 FEBS 12461 
‘0 1993 Federatton of European Biochemical Socteties 00145793/93/$6 00 
May 1993 
Liver-enriched HNF-3a and ubiquitous factors interact with the human 
transferrin gene enhancer 
Corinne Aug&Gouillou, Isabelle Petropoulos and Mario M. Zakin 
Unit& d’E.upression des G&es Eucar~vtes. hstitut Pasteur. 28 rue du docteur Rous. 75724 Paris Cedes 15. France 
Received 1 April 1993 
The human transferrin gene enhancer is orgamzed in two domains. Domain A contains a smgle enhanson designated la. Domain B contams four 
enhansons named lb, Il. III and IV. We demonstrate here that the hver-enriched transcription factor HNF-3a interacts with enhanson Ia and that 
enhansons Ib and IV are binding sites for members of the NFI family. In addition, enhansons II and III seem to be respecttvely the targets for 
the AP4 protein and for EIII, a factor not yet completely identified Analysis of mutated enhancer regions establishes that each enhanson IS required 
for full enhancer activity and that the proteins binding to enhansons II, III and IV may interact wnhm a multtprotein complex. This enhancer region 
presents no activity in the Sertoh cells of testis, where transferrin is also synthesized. We demonstrate that in Sertoli cells, the members of the HNF-3 
family are not expressed: this fact may account for the Inactivity of the enhancer m these cells 
Transferrin: Enhancer: Liver. Hepatoma cell. Sertoh cell. Transcription factor 
1. INTRODUCTION 
Transferrin (Tf) is an iron-binding glycoprotein es- 
sentially synthesized in hepatocytes, and in lower 
amounts in other cell types like Sertoli cells of testis and 
different cellular populations of the central nervous sys- 
tem [l-3]. Human transferrin gene expression in 
hepatoma cells is modulated by a combination of multi- 
ple positive and negative &-acting elements [4.5]. These 
elements are distributed in four functionally different 
regions, and one of these regions, situated between -3.6 
and -3.3 kb upstream of the transcription start site of 
the gene, fulfills the criteria established for enhancers 
[5]. This enhancer is composed of five enhansons. inter- 
acting with at least four nuclear proteins and organized 
in two domains A and B (Fig. 1) which act in synergism 
[6]. It is active in transient expression experiments per- 
formed in Hep3B cells, but no enhancer activity can be 
associated to this sequence in assays performed in pri- 
mary cultures of Sertoli cells [7]. 
Full understanding of the mechanisms leading to the 
differential activity of the enhancer in several cell types 
needs the identification and the characterization of the 
properties of the transcription factors involved. 
In this paper, we identified three of the factors re- 
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quired for full enhancer activity in hepatoma cells and 
we showed that one of them is a liver-enriched protein. 
Furthermore, we have clarified the relative contribution 
of each of the factors to the overall activity of the enhancer 
as well as some aspects of its structural organization. 
Finally, as a first step to understand the molecular 
basis of the inactivity of the enhancer in Sertoli cells, we 
investigated the presence of the liver-enriched factor in 
these cells. 
2. MATERIALS AND METHODS 
T4 DNA ligase. DNA polymerase I (Klenow fragment), T4 polynu- 
cleottde kmase and restriction endonucleases were purchased from 
New England BioLabs. Inc.: DNase I from Worthmgton; alkaline 
phosphatase and Ham’s F-I’-modified Eagle’s medium from Boehrin- 
ger Mannhetm: PolytdIdC) and Taq polymerase from Pharmacta 
LKB Biotechnology Inc.: ‘%-labeled chloramphemcol. “S-labeled 
methionine and “P-labeled dNTPs from Amersham Corp.: acetyl co- 
enzyme A from Sigma 
The wild-type enhancer, obtained from the t-3.600,+39)Tf-CAT 
plasmid [5] by EcoRI and HrridIII digestion and filled in. was first 
cloned into the SrncrI site of the pUCl9 polylinker. This construction 
was named (0.3)pUCl9. Mutations of the hTf enhancer were intro- 
duced by the polymerase cham reaction (PCR) usmg the (0,3)pUCl9 
as a template. We used mutated ohgonucleottdes as internal primers, 
universal (U.P.) and reverse (R.P) primers with NdeI ends 
(U.P (NdeI): R.P.th’deI)) as external primers (for sequences see Table 
I). The mutated fragments were obtamed after digestion of the final 
PCR products by A’deI. Altered enhancers obtained by PCR mut- 
agenesis are named eMIb, eMI1, eMIlI and eMIV 
Four altered enhancers were cloned mto the N&I site of 
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(-620,+39)Tf-CAT plasmid [5] to obtain (eMIb)pTf-CAT, 
(eMII)pTf-CAT, (eMIII)pTf-CAT, (eMIV)pTf-CAT, respectively. 
2.4. Preparation of nuclear extracts 
Liver nuclear extracts were prepared according to the procedure of 
Gorsky et al. [S] with minor modifications [4]. 
HeLa cells and Hep3B cells nuclear extracts were prepared accord- 
mg to the procedure of Brunel et al. [4]. 
2.5. In vitro transcription und translation 
T7 RNA polymerase was used to synthesize HNF-3a RNA from 
a BarnHI-linearized cDNA template (pGem-1). In vitro translation 
was performed using nuclease-treated rabbit reticulocyte lysate ac- 
cording to the manufacturer’s protocol (Promega). in a final volume 
of 25 ,Ul. 
The crude reticulocyte lysate containing translated proteins was 
used directly in either gel mobility shift assays or in DNase I foot- 
printing experiments. 
2.6. Electrophoretic mobilrty sh$t assa.vs (EMSA) 
The standard assay as well as the competition experiments were 
performed as previously described [9] using 6 pg of nuclear extracts 
or 2 ~1 of in-vitro translated HNF-3a. 
HNF-3(cc, /3 and y) rabbit anttsera and NFl rabbit antiserum were 
used to analyze purified proteins or crude nuclear extracts. 1 ~1 of 
serum, diluted IO-fold of phosphate-buffered saline (for HNF-3 anti- 
sera) or undiluted (for anti-NFl serum), was incubated overnight at 
4°C with 10 ~1 of protein preparations. Then. the assays were per- 
formed under standard conditions. The same experiments were carried 
out with serum from a non-immunized rabbit. 
2.1. DNase I footprints 
These expertments were performed as described before [4]. The 
probe was the mutated enhancers obtained from the different con- 
structions by digestion with EcoRI and Hind111 and labeled at the 
EcoRI site. Assays were performed with 30 pg of crude hver nuclear 
extracts, 
2.8. Ceil cultures und chloramphemcol acetyltransferase assays 
Hep3B cell cultures, transfecttons and chloramphenicol acetyltrans- 
ferase assays were performed as previously described [5]. 
2.9. Northern blot assays 
Total cellular RNA were prepared from Hep3B or rat Sertoli cells 
using the Btoprobe System RNAzol B, according to the manufac- 
turer’s procedure. PolyA(+)RNA obtained by chromatography of 
total RNA through an oligo(dT) affinity column [lo] were electro- 
phoretically separated on a 1% formaldehyde-agarose gel and trans- 
ferred to a nitrocellulose membrane (Hybond-C). The blot was hybrid- 
ized wtth a DNA probe corresponding to the DNA bmdmg domam 
of HNF-3a. The 356-bp probe was obtamed by PCR. usmg the HNF- 
3a cDNA as template and the followmg ohgonucleotides as primers 
CATCACCATGGCCATCCAGC; CAGCTACCATGGATCATT- 
TGCGGTTTTCTGGGACCC and was labeled using the Megaprime 
DNA labeling system (Pharmacia). 
3. RESULTS 
3.1. HNF-3a interacts with the Tf enhancer domain A 
Domain A, which has been described as the active 
part of the enhancer, contains a single enhanson Ia, 
which is a binding site for two liver proteins. These 
proteins. named EBP-45 and EBP40. have been puri- 
fied from rat liver nuclear extracts by affinity chroma- 
tography [l I]. However, EMSA performed with 
oligonucleotide 11 (corresponding to the motif Ia, see 
Table I and Fig. 1) show that EBP-40 is largely repre- 
-3600 bp -3300 bp 
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Fig. 1. Dlagrdm of the hTf enhancer. Boxes represent the five motifs 
as indtcated inside. Domain A 1s represented by a white box. Domain 
B by grey boxes. -3,600 bp and -3,300 bp are the limits of the 
enhancer relative to the cap site of the hTf gene. 1, 86 and 291 desig- 
nate nucleotide numbers of the enhancer. Oligonucleotides used in this 
paper are depicted as broken lines under then corresponding motifs. 
sented in Hep3B nuclear extracts whereas EBP-45 is 
only poorly detected (Fig. 2a). This suggests that the 
activity observed in transient expression experiments is 
essentially due to EBP40. 
Recent studies have indicated that HNF-3. a family 
of liver-enriched transcription factors, could recognize 
the motifs 5’-TGTTTGTTTCT-3’ [12] or S- 
TGTTTGTTTT-3P’ [13] closely related to the motif 
present in the core of the enhanson Ia. In order to test 
whether EBP-40 belongs to the HNF-3 protein family, 
we used antisera directed against HNF-3a, HNF-3p or 
HNF-3y in gel mobility shift assays. Fig. 2b shows that 
the antiserum directed against HNF-3a is the only one 
that reacts with EBP-40 (which forms the slower com- 
plex in gel shift experiments) preventing the binding of 
the protein to the DNA. Moreover, as shown in Fig. 2c, 
Table I 
Sequence of oligonucleotides used in this paper 
IV2 
*“am”t 
We report only the sequences of the upper strands. Numbers indicate 
the positions of the nucleotides m the enhancer region, excepted for 
the oligonucleotide CR where numbers indicate the position relative 
to the cap sate. Mutated ohgonucleotides have been realized according 
to the ‘preferential bmdmg sites’ of the wild-type ohgonucleotides 
(Botssier et al. [6]). The nucleotides mutated from the wild-type se- 
quence are indicated in lower-case letters. Concerning the oligonucle- 
otide 1112, astertsks indicate the purines for whtch methylatton inter- 
feres wtth binding. 
5 





- nis c( p y I1 I1 mu12 ---- 
(1 
1 2 345 12345678 
b c 
probe II 
Fig. 2. Analysis of the interaction of HNF-3a with the A domam of 
the hTf enhancer EMSA were performed with ohgonucleotlde I1 as 
a probe. (a) Hep3B or rat liver nuclear extracts were used as indicated. 
(b) Assays performed m the presence of co-purified EBP-40 and EBP- 
45, and different sera. Lane 1, assay without serum, lane 3, assay 
performed with serum from nommmumzed rabbits; lane 3. assay per- 
formed with serum from rabbits Immunized against HFN-3a: lane 4. 
assay performed with serum from rabbits Immunized agamst HFN-3/I: 
lane 5, assay performed with serum from rabbits immunized against 
HNF-3y. (c) Lane 1. assay performed m the presence of co-purified 
EBP-40 and EBP-45: lane 2. assay performed with m-vitro translated 
HNF-3a; lanes 3-5. competltion experiments were performed with a 
IO-. 50- or IOO-fold excess of unlabeled oligonucleotlde 11, m the 
presence of m-vitro translated HNF-3a; lanes 6- 8. competitlon exper- 
iments were performed with a lo-, 50- or IOO-fold excess of unlabeled 
oligonucleotide Ilmut-2. in the presence of m-vitro translated 
HNF-3a. 
the complex formed in EMSA between the Ia sequence 
and the purified EBP40 is identical to the one obtained 
with the in-vitro translated HNF-3~ protein (tHNF- 
301). Furthermore. unlabeled oligonucleotide 11 is able 
to compete for the formation of the DNA/tHNF-301 
complex. On the contrary, its formation is not inhibited 
by the addition of increasing amounts of the mutated 
oligonucleotide Ilmut-2 (see Table 1 and Fig. 2~). In- 
deed, this oligonucleotide fails to generate complexes 
with EBP-40 [1 l] and with tHNF-3a: (not shown). 
From all these data we conclude that EBP-40, the 
protein that interacts with the enhanson Ia, is HNF-3a. 
3.2. IdentiJcation of the proteins interacting ,tlitlz the Tf 
enhancer domain B 
3.2.1. Factors belonging to the NFl protein family in- 
teract with motifs Ib and IV 
In-vitro DNA-protein binding experiments sug- 
gested that oligonucleotides 12 and IV2 (corresponding 
respectively to motifs Ib and IV) are the target for the 
same protein [6]. To identify this protein we performed 
cross competition gel shift assays with a 1 OO-fold excess 
of several oligonucleotides described as binding sites for 
known nuclear factors. One of them, the oligonucleo- 
tide CR (Table I) is able to compete for the formation 
of the complex obtained with liver extracts and the la- 
beled oligonucleotides 13 or IV2 (Fig. 3a). CR corre- 
sponds to a region of the hTf promoter which interacts 
with transcriptional factors belonging to the NFl pro- 
tein family [4]. In order to clearly identify the factors 
binding on the motif Ib and IV, we used antibodies 
directed against members of the NFl protein family [14] 
in gel retardation assays. As shown in Fig. 3b, the anti- 
serum interacts with most of the proteins involved in the 
formation of the retarded complexes. preventing their 
binding to the probes IV2 and 12. 
Finally. mutation of the TGG sequences present in 
motifs Ib and IV. and corresponding to a half binding 
site for the NFl factors, inhibits their interactions with 
the liver proteins (see below). From all these results, we 
conclude that motifs Ib and IV, as the CR region of the 
hTf promoter, interact with proteins belonging to the 
NF 1 family. 
3.22. The factor interacting with motif II 
Motif 11 corresponds to the sequence 5’- 
CTGCTGGTCAGCTT-3’ [6]. This sequence contains -___ 
part of the transcription factor AP4 binding site 
CAGCTG [I 5.161. in two repeats (nucleotides corre- 
sponding to the AP4 binding site are underlined in the 
motif II sequence). First, EMSA have been realized with 
HeLa and liver nuclear extracts using an oligonucleo- 
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Fig. 3. Gel shift analyses of oligonucleotides I2 and IV2. In each case, 
assays were performed with crude liver nuclear extracts. Probes are 
the ohgonucleotldes IV2 or I2 as Indicated. (a) Cross competltlon 
experiments usmg a lOO-fold excess of homologous or CR ohgonucle- 
otlde as mdlcated (b) Analyses usmg serum from rabbits Immunized 
against NFl Lane 1. assay without serum: lane 2. assay with the 
pre-Immune serum. lane 3. assay performed m the presence of ant]- 
aerum. 
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clear proteins. One of them, APFI (Table I), is able to 
compete for the formation of the retarded band between 
the liver protein and the oligonucleotide 1112 (Fig. 4~). 
The oligonucleotide APFI corresponds to an element of 
the apolipoprotein Cl11 promoter [17,18] which inter- 
acts with several liver nuclear factors giving rise to two 
retarded complexes [19]. The protein CIIIBI , forming 
the slower complex, was recently purified but not yet 
cloned [20]. The proteins involved in the formation of 
the faster complex were demonstrated to be HNF4. 
COUP-TF and Arp-1 [21]. The retarded band we ob- 
served in EMSA with the oligonucleotide 1112 has the 
same electrophoretic mobility as the complex due to 
CIIIBl. Moreover, unlabeled oligonucleotide 1112 is 
able to compete for the formation of the CIIIBl com- 
plex but not for the faster one (Fig. 4~). In addition, the 
protein interacting with motif III is, like CIIIBl, a heat 
stable factor (data not shown). These results indicated 
that the liver nuclear factor interacting with the motif 
III of the hTf enhancer might be CIIIBl. However, 
competition experiments showed that the oligonucleo- 
tide 1112 was unable to compete for the binding of puri- 
fied CIIIBl to the oligonucleotide CIIIBMS. a mutated 
probe that binds only CIIIBl [20] (Dr. Zannis, personal 
communication). 
Fig. 4. Characterization of the proteins interacting v&h the oligonu- 
cleotides II1 and 1112. (a) Gel shift assays were performed with liver 
or HeLa cells crude nuclear extracts as indicated. The ohgonucleotlde 
AP4 was used as a probe. (b) Cross-competition experiments were 
performed in the presence of crude liver nuclear extracts. Ohgonucle- 
otides II1 or AP4 were alternatively used as probes. A lOO-fold excess 
of competitor oligonucleotide II1 or AP4 was used as Indicated. (c) 
Assays were performed with crude hver nuclear extracts. Ohgonucleo- 
tides III2 and APFl were alternatively used as probes. For competi- 
nons, a 100-fold excess of unlabeled oligonucleotides III2 or APFI 
was used. Arrow A indicates the band correspondmg to EIII complex. 
arrow B indicates the band corresponding to HNF-4, COUP-TF and 
Arp-I complexes. 
tide containing the AP4 binding site present in the SV4O 
enhancer A-domain [15] (Table I). As shown in Fig. 4a, 
a similar complex is obtained with both extracts, indi- 
cating that the factor AP4, first purified from HeLa cells 
[15], is also present in liver extracts. Then, cross compe- 
tition assays were performed between the oligonucleo- 
tides AP4 and 111 (corresponding to the hTf enhancer 
motif II). Data shown in Fig. 4b indicate that with liver 
extracts, the heterologous as well as the homologous 
oligonucleotide is able to compete for the formation of 
the oligonucleotide-protein complex. Results are the 
same with HeLa extracts (not shown). In addition, dis- 
ruption of the GCTG sequence present in motif II, es- 
sential for AP4 binding, inhibits its interaction with the 
factor present in the liver nuclear extracts (see below). 
Taken together, these results indicate that AP4 is likely 
to interact with motif II of the hTf enhancer. 
3.2.3. The factor interacting with motif III 
EMSA have shown that a single liver nuclear factor 
interacts with the oligonucleotide 1112 which corre- 
sponds to motif III. In order to identify this factor, we 
performed cross competition assays with several ol- 
igonucleotides described as binding sites for known nu- 
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From these results, we conclude that at the moment 
we are not able to fully identify the protein that interacts 
with the motif III of the hTf enhancer. This protein is 
provisionally named EIII. 
3.3. Effects of‘ domain B mutations on protein binding 
and on trunscription activation 
In order to determine the contribution of each motif 
of the domain B to the enhancer activity, we performed 
mutagenesis experiments. The mutated oligonucleotides 
used for this purpose are depicted in Table I. The ol- 
igonucleotides 12 and IV2 were modified in a TGG 
motif corresponding to a half binding site for the NFl 
factor family (oligonucleotides 12mut and IV2mut). The 
oligonucleotide 111 which seems to be a target site for 
the AP4 factor, was modified in the motif GCTG corre- 
sponding to part of the AP4 binding site (oligonucleo- 
tide IIlmut). Concerning the oligonucleotide 1112, inter- 
acting with EIII, the mutations were chosen in order to 
disrupt the main protein-DNA contact points deter- 
mined by methylation interference assay (oligonucleo- 
tide 1112mut, Table 1). 
Each mutated oligonucleotide has lost the ability to 
bind the nuclear factor interacting with the correspond- 
ing wild type sequence. as demonstrated by gel mobility 
shift and DNase I footprinting competition experiments 
(data not shown). 
3.3.1. In vitro analysis of mutated enhancers 
Mutations were then introduced by PCR in the hTf 
enhancer to produce four modified enhancers: eMIb, 
eMI1, eMII1 and eMIV respectively mutated in the mo- 
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Fig. 5. Effect of region B mutations on protein binding and on tran- 
scription activation. (Upper part) Schematic representation of results 
obtamed m footprmtmg experiments with the wild type and the four 
modified enhancers eMIb. eMI1, eMI and eMIV (as Indicated on the 
left). Boxes representing the five motifs are Indicated and summarize 
the presence or the absence of DNA-protem utteractions. Motif Ia is 
represented as a dark box. Motifs of the domam B (Ib, II, III and IV) 
are represented as clear boxes. Stars are pointing out the mutated 
mottfs. (Lower part) Analysis of the transcriptional activity of the 
mutated enhancers. Values are the percentage of CAT activity m 
transient expression experiments using Hep3B cells They represent 
the means * S.E M. for at least three independent experiments and are 
expressed relattve to the Enh pTf-CAT activity. 
tifs Ib, II, III and IV. DNase I footprint analyses were 
performed using the four modified enhancers, in the 
presence of crude nuclear extracts. The results are sum- 
marized in Fig. 5 (upper part). As expected, eMIb af- 
fords no protection on the mutated motif Ib. indicating 
that NFI is unable to interact with the Ib modified site. 
Mutations in the motif II of eMI prevent not only the 
binding of AP4 to this motif but also interfere with the 
binding of EIII to motif III. On the other hand, no 
modification of the protection over the five motifs Ia, 
Ib. II, III and IV is observed in both modified enhancers 
eMII1 and eMIV. These results indicate that protein- 
protein interactions may exist between the factors AP4, 
EIII and NFl bound respectively to motifs II, III and 
IV (see section 4). 
3.3.2. Transcriptional activity of the four modified en- 
hancers 
The four mutated enhancer regions (eMIb, eMI1, 
eMII1 and eMIV) have been cloned upstream of the hTf 
promoter in a CAT reporter plasmid to be tested in 
transient expression experiments in Hep3B cells. As 
controls, we used a vector containing the wild type en- 
hancer (Enh pTf-CAT) and a vector containing only the 
hTf promoter (pTf-CAT). The four mutated enhancers 
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present reduced activity (Fig. 5, lower part). eMIb pTf- 
CAT and eMI pTf-CAT show residual activities which 
are respectively 50% and 28% of that of the wild type. 
eMII1 pTf-CAT has a slighter effect on the enhancer 
activity (residual activity of 71%). On the contrary, 
eMIV pTf-CAT has lost the ability to enhance the effect 
of the hTf promoter. It is interesting to underline that 
these functional results are not always in keeping with 
the footprinting analyses of the mutated enhancer re- 
gions (see Fig. 5). 
3.4. The members of the liver-enriched HNF-3 transcrip- 
tion factor family are not expressed ill the Sertoli 
cells of testis 
The proteins we have already identified as binding to 
the domain B are rather ubiquitous than liver-specific. 
On the contrary, domain A interacts with HNF-3a, a 
liver-enriched transcription factor [22]. One of the ques- 
tions that may be addressed concerns the possible corre- 
lation of the efficiency of the enhancer in different cell 
types with the presence or the absence of HNF-3. This 
prompted us to analyze the existence of the HNF-3 
messengers in Sertoli cells where the transferrin gene is 
functionally transcribed but the enhancer inactive [7]. 
Northern blot analyses of poly(A)’ RNA from Sertoli 
and Hep3B cells demonstrate that no messenger of any 
of the members of the HNF-3 protein family is detected 
in Sertoli samples while they appear in Hep3B samples 
(Fig. 6). Nevertheless, a Sertoli protein is able to inter- 
act in EMSA with an oligonucleotide containing the A 
domain sequence [7]; however, this protein is not recog- 
nized by antisera directed against members of the HNF- 
3 family of proteins (not shown). 
4. DISCUSSION 
4.1. IdentiJication qf the nuclear proteins interacting 
Judith the hTf enhancer 
As a first step in the understanding of the molecular 
mechanisms involved in the Tf enhancer activity we 
identified most of the nuclear proteins interacting with 
this region. 
Sertoli Hep3B 
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Fig. 6. Northern blot analysis of poly(A)’ mRNA from Hep3B and 
Sertoh cells. Messengers coding for members of the HNF-3 protein 
family were detected with the region of the HNF-3a cDNA corre- 
sponding to the DNA bmdmg domam of the protein. Traces of ‘8 S 
and 18 S rRNAs were present m the samples. 
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Fig. 7. Diagram of the hTf enhancer organization. Boxes represent the 
five motifs as indicated inside The motif la (domain A) IS represented 
as a white box. The four motifs of the domain B (motifs lb, II, III and 
IV) are represented as grey boxes. Factors interacting with each motif 
are Indicated under each box. Numbers locahze the position of the 
enhancer relative to the cap site of the human transferrin gene. 
We have previously described the purification of two 
liver nuclear factors, EBP-40 and EBP-45, interacting 
with the enhanson Ia of the domain A [l 11. Compared 
to EBP-45, EBP-40 is largely represented in Hep3B nu- 
clear extracts (Fig. 2a); furthermore. EBP-40 presents 
a higher affinity than EBP-45 for the motif Ia [ll]. 
These data indicate that EBP-40, rather than EBP-45. 
is involved in the hTf enhancer activity detected in 
hepatoma cells. We thus focused our attention to its 
identification. Using specific antisera we showed that 
EBP-40 is identical to HNF-3a (Fig. 2b). Since we puri- 
fied a protein of 40 kDa and since HNF-301 is a protein 
of 50 kDa [22], it seems likely that we purified a prote- 
olytic form of HNF-3a. 
The use of specific antisera allows the identification 
of the proteins interacting with motifs Ib and IV of the 
hTf enhancer as belonging to the NFl family (Fig. 3b) 
[14]. In addition, mutagenesis as well as gel shift exper- 
iments have shown that the protein interacting with 
motif II is likely to be AP4 (Fig. 4) [16]. Finally, it has 
not yet been possible to clearly identify EIII, the protein 
interacting with enhanson III. 
All these results are summarized in Fig. 7. 
4.2. Organization of the hTf enhancer 
After identification of the proteins interacting with 
the different motifs of the enhancer, mutagenesis exper- 
iments have clarified the relative contribution of each 
enhanson to its activity. The data concerning domain B, 
obtained in this paper from transient expression experi- 
ments (Fig. 5, lower part), as well as the results previ- 
ously reported with domain A [1 11. indicate that each 
motif (or module) is necessary to obtain full enhancer 
activity. 
Furthermore, results of the footprinting experiments 
performed with the mutated enhancers, illustrate some 
aspects of the enhancer organization. 
Analyses of the footprinting patterns obtained with 
eMlb, modified in region 1 b, indicate that this region 
is unable to bind NFl (Fig. 5. upper part). As all other 
motifs of the enhancer are still protected, we conclude 
that the binding of NFl to motif Ib occurs independ- 
ently of the other factors. The same conclusion was 
obtained previously concerning the binding of HNF-3cl 
(EBP-40) on motif Ia [l 11. 
eMI1, modified at the AP4 binding site, is unable to 
bind AP4 and surprisingly, is also unable to bind EIII 
(Fig. 5, upper part). On the contrary, the footprinting 
pattern of the eMII1 enhancer, shows a protection at the 
mutated EIII binding site as well as at the other sites. 
Taken together, these results suggest that there is a 
direct interaction between AP4 and EIII. Indeed, the 
EIII protein seems to bind to enhanson III only when 
AP4 interacts with its own target, enhanson II. It is then 
tempting to suggest that EIII protects the modified 
motif III in the eMII1 footprinting experiments, 
through its interaction with AP4. Consequently, in the 
wild-type enhancer, EIII may have two contacts, with 
the DNA and with the neighboring factor AP4. In 
eMII1, EIII would only have one contact, with AP4, 
sufficient to protect enhanson III against DNase I 
cleavage. 
Similar analyses were made with eMIV; in spite of the 
fact that the mutation introduced in motif IV was 
shown to abolish NFl binding in in-vitro experiments, 
all the motifs are protected in the footprinting assays 
(Fig. 5. upper part). These results suggest, in this case, 
the existence of interactions between the NFl factor and 
other proteins. Since the binding of HNF-3a and NFl 
to motifs Ia and Ib occurs independently of the other 
factors (see above), it is logical to propose that the NFl 
protein, binding to motif IV, may interact with the pro- 
posed AP4-EIII complex. The hypothesis concerning a 
multimeric complex formation between AP4, EIII and 
NFl is supported by the known properties of the AP4 
factor. Indeed, Hu et al. [16] suggested that AP4 could 
interact selectively with a variety of different proteins. 
The hTf enhancer presents, as others cellular and 
viral enhancers, a modular organization and an abso- 
lute requirement of each module for full enhancer activ- 
ity. The hTf enhancer, associated with liver-enriched 
and ubiquitous proteins constitutes a particular molecu- 
lar edifice specifically maintained through DNA-pro- 
tein and protein-protein interactions. Such a molecular 
organization may have important physiological conse- 
quences: a variation in the amount of a single factor 
should result in a drastic modification of the enhancer 
activity. Indeed. the absence of efficiency of the en- 
hancer sequence in Sertoli cells [7] could be explained 
in this way. 
4.3. Molecular basis of the irlactivity of the enhancer in 
Sertoli cells 
The factors we have sofar identified as interacting 
with domain B of the enhancer in the hepatic system are 
rather ubiquitous than tissue-specific. On the contrary, 
domain A is the binding site for a member of the HNF-3 
transcription factor family. Since this factor is a liver- 
enriched protein [22], we asked whether or not HNF-3 
proteins are also present in Sertoli cells. It was previ- 
ously shown that messengers for the HNF-3y protein 
are present in whole testis RNA [23]. We demonstrate 
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here that no messengers of the HNF-3 family can be 
detected by Northern blots in Sertoli cell preparations 
(Fig. 6). Nevertheless, a protein is able to interact with 
an oligonucleotide containing the enhanson Ia in gel 
shift mobility: this interaction was shown to be specific 
by competition experiments [7]. However, this protein 
is not recognized by antisera directed against any of the 
members of the liver-enriched HNF-3 family. Moreo- 
ver, footprinting experiments performed with the whole 
enhancer DNA region indicate that domain A is not 
protected or very weakly protected when using Sertoli 
or testis crude nuclear extracts [7]. Therefore, it is 
tempting to correlate the absence of the HNF-3 proteins 
with the non-functioning of the enhancer in Sertoli cells. 
Acknowledgments We are grateful to G.N. Cohen and N. Duchange 
for helpful discusstons and critical readmg of the manuscrtpt, to W. 
Chen and J.E. Darnell Jr. for provtding the antisera directed against 
HNF-3a, p and y, to R.H. Costa for the HNF-3a cDNA-pGem-1 
expresston vector, to N. Tanese and R. TJian for the anttserum di- 
rected against NFl and to F. Gutllou for total RNA from Sertoli cells. 
We also thank E. Croullebois for her help in the preparation of this 
manuscrtpt. This work was supported by the Centre National de la 
Recherche Scientifique (Unite de Recherche Associee 1129) and by the 
Associatton pour la Recherche contre le Cancer (ARC). C.A.-G. and 
I.P. are predoctoral fellows of the Ministere de la Recherche et de la 
Technologte (France). 
REFERENCES 
[1] Morgan, E.H. (1969) J. Biol. Chem. 244. 41934199. 
[2] Skinner, M.K. and Griswold, M.D. (1980) J. Btol. Chem 255, 
952339525. 
[3] Aldred, A.R., Dickson, P.W.. Morley, P.D. and Schretber. G. 
(1987) J. Biol. Chem. 262, 529335297. 
[4] Brunel, F , Ochoa. A., Schaeffer, E.. Botssier. F.. Gutllou, Y., 
Cereghini, S., Cohen, G.N and Zakin, M.M. (1988) J. B~ol. 




















Schaeffer. E., Boisster. F., Py, MC., Cohen, G.N. and Zakin, 
M.M. (1989) J. Biol. Chem. 264, 715337160. 
Boissier, F., AugC-Gouillou. C., Schaeffer, E. and Zakin. M.M. 
(1991) J. Biol. Chem. 266. 9622-9628. 
Gmllou, F., Schaeffer. E.. Part, D. and Zakm, M.M. (1991) J. 
Biol. Chem. 266, 98769884. 
Gorsky, K.. Carneiro. M and Schtbler. H. (1986) Cell 47, 7677 
776. 
Ochoa. A.. Brunel. F.. Mendelzon. D.. Cohen. G.N. and Zakm, 
M.M (1989) Nucletc Actds Res. 17. 119-133. 
Aviv, H. and Leder. P. (1972) Proc. Natl. Acad. SCI. USA 69. 
1408-1412 
Petropoulos, I.. Auge-Goutllou. C and Zakm. M.M. (1991) J. 
Biol. Chem 266. 24220-24225. 
Zaret, K.S., Liu. J.K. and Dipcrsto. C.M. (1990) Proc. Nat]. 
Acad. Sci. USA 87. 546995473. 
Pani, L . Qtan, X., Clevidence, D. and Costa, R.H. (1992) Mol. 
Cell. B~ol. 12, 552-562. 
Mermod, N , O’Netll. E.A . Kelly. T.J. and TJian, R (1989) Cell 
58, 741-753 
Mermod. N.. Wtlliams. T.J and Tjtan, R (1988) Nature 332, 
557-561. 
Hu. Y.F . Ltischer, B., Admon. A.. Mermod, N and Tjtan. R. 
(1990) Genes Dev. 4. 1741-1752. 
Reue. K.. Leff. T and Breslow. J.L. (1988) J. B~ol. Chem. 263. 
6857-6864. 
Costa, R.H.. Van Dyke, T.A., Yan, C., Kuo, F. and Darnell Jr., 
J.E. (1990) Proc. Nat]. Acad. Sci. USA 87. 6589-6593. 
Ogami, K . Hadzopoulo-Cladaras, M., Cladaras, C. and Zannis, 
V.I. (1990) J. B~ol. Chem. 265, 98089815 
Ogamt, K.. Kardassis, D., Cladaras. C. and Zannis, V.l (1991) 
J Biol. Chem. 366, 9640-9646. 
Mietus-Snyder. M.. Sladek, F.M., Ginsburg, G.S.. Kuo, C.F.. 
Ladias, J.A.A.. Darnell Jr.. J.E. and Karathanasts. S.K. (1992) 
Mol. Cell. Btol. 12, 1708~1718. 
Lai. E., Prezioso, V.R., Smith, E.. Lttvin, O., Costa, R.H and 
Darnell Jr.. J.E (1990) Genes Dev 4, 1427-1436. 
Lai, E., Preztoso. V.R.. Tao, W., Chen. W.S. and Darnell Jr., J.E. 
(1991) Genes Dev. 5. 416327. 
10 
